Ralph Lauren Announces Updates to Board of Directors
NEW YORK--(BUSINESS WIRE)--Ralph Lauren Corporation (NYSE: RL) today announced that, as part of its Board of Directors evolution strategy, it has approved the appointment of Angela Ahrendts as new Lead Independent Director following the Company's 2025 Annual Meeting of Shareholders. Ahrendts has served on the Ralph Lauren Board since August 2018 and is currently the Finance Committee chair and a member of the Nominating, Governance, and Sustainability Committee.
Ahrendts succeeds Hubert Joly, who, after 16 years of service, will not seek reelection to the Company's Board of Directors. Joly was appointed to the Ralph Lauren Board in June 2009 and has served as Lead Independent Director since 2021. He currently sits on the Talent, Culture & Total Rewards and Finance Committees. Joly played a key role in the Board's evolution, resulting in its broadened diversity of backgrounds, skills and experiences.
'Hubert has been an integral part of our board and has been instrumental in guiding and supporting our strategy, while embodying the passion and dedication that define our brand. We are grateful for his unwavering support and thoughtful leadership as well as the care he has shown for our Company and our teams,' said Ralph Lauren, Executive Chairman and Chief Creative Officer.
'Angela has consistently offered valuable guidance and brought her perspective as a respected innovator in the industry. We look forward to continuing to benefit from her leadership and contributions as our new Lead Independent Director,' Ralph Lauren added.
'We are proud to have a Board comprised of deep, unique and differentiated experiences, all of which continue to contribute to our strength and durability as a business. I am grateful for Hubert's guidance over the years, particularly in helping drive our Company's performance and transformation and I look forward to working closely with Angela in her expanded role,' said Patrice Louvet, President & Chief Executive Officer.
With Mr. Joly's departure, the Ralph Lauren board will be comprised of 11 directors. Ms. Ahrendts's appointment as the new Lead Independent Director will be effective following her re-election as a director at the 2025 Annual Meeting of Shareholders, taking place on Thursday, July 31, 2025.
ABOUT RALPH LAUREN CORPORATION
Ralph Lauren Corporation (NYSE:RL) is a global leader in the design, marketing, and distribution of luxury lifestyle products in five categories: apparel, footwear & accessories, home, fragrances and hospitality. For nearly 60 years, Ralph Lauren has sought to inspire the dream of a better life through authenticity and timeless style. Its reputation and distinctive image have been developed across a wide range of products, brands, distribution channels, and international markets. The Company's brand names — which include Ralph Lauren, Ralph Lauren Collection, Ralph Lauren Purple Label, Polo Ralph Lauren, Double RL, Lauren Ralph Lauren, Polo Ralph Lauren Children, and Chaps, among others — constitute one of the world's most widely recognized families of consumer brands. For more information, go to https://corporate.ralphlauren.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vogue
28 minutes ago
- Vogue
Ralph Lauren Spring 2026 Menswear Collection
Even as the USA's reputational stock falters, global regard for Ralph Lauren—the most all-American of American brands—is on the up: Vogue Business last month reported the company's sales in Europe and China had increased 12 per cent and 9 per cent respectively in the fiscal year 2025. That uptick means that the majority of the company's total $7.1 billion of revenue for the same period was generated beyond the Land of The Free. So during a period where luxury more broadly has also been faltering, how has RL been bucking the trend two-fold? This evening's Ralph Lauren Purple Label pointed to at least part of an answer. Once you'd steered beyond the vintage car in the courtyard, the presentation was split into two sections. The first cluster of looks were garments for an idealized version of the New York Yacht Club: wearable American magic. Navy washed against white on a piped terry boating blazer worn with a bengal stripe shirt and cravat over pleated linen shorts and ankle-strapped espadrilles. A four-button (silver) navy double breasted blazer with ersatz branded club badge was commodore-level quality. Thickly woven textured silk navy short sleeve shirting and drop shoulder color block knits, or classic Ralph (via the Marylebone Cricket Club) cable-knit sweaters all added to the breezy feel. The next section, housed in the brand's Milan palazzo's first-floor courtyard, was a tonal triumph. Of the maybe 25-strong cast of globally-sourced heartthrobs, around 23 wore shades running from the pale khaki of a game-pouched fishing jacket over a safari shirt and action pant to the richly-burnished, nutty brown of a distressed leather flight jacket with complementarily-strapped pilot's watch. From the slubby silk linen windowpane check field jackets to the tailored linen takes on mid-century military shirting via the darker interjections of art-deco intarsia tuxedo jackets, these were clothes for sophisticated yet unstuffy heroes. The jaunty cravats and woven short sleeve shirting recalled Cary Grant as John Robie The Cat; the masterful khakis were slimmed down Hemingway fare for living large on The Keys; and the flight jacket and tux were prime Pitt and Clooney material. Lauren has always said he designs cinematically: this was American luxury that evoked a reassuring, aspirational, and highly-idealized version of its homeland—and which seemed all the more desirable thanks to that vision's current distance from reality.
Yahoo
2 hours ago
- Yahoo
Retail Traders Just Sent This AI Health Stock Soaring 60%
Oscar Health (NYSE:OSCR) has exploded nearly 60% this week, adding close to $2 billion in market cap without a single press release or earnings update. The real catalyst? A retail trading frenzy. OSCR became one of the most-mentioned names on r/WallStreetBets, and trading volume followed suitnearly 50 million shares changed hands on Wednesday alone, the second-highest in the company's history. Options activity lit up as well, with call volumes hitting a record 152,414 that day, and another 95,000 contracts moving by Friday morning, nearly triple the norm. Beneath the surge is a company with serious revenue momentumup 48% in 2023 and 57% in 2024. Adjusted earnings per share reached $0.92 in Q1 2025. But Oscar isn't just selling insuranceit's selling a story. Management brands the company as a health-tech platform, powered by AI and run on what it calls a continuous hackathon model. That pitch, familiar to anyone who's followed high-multiple tech names, is likely helping Oscar catch a more generous valuation than traditional insurers. Retail traders appear to be buying into that promise. Another factor? The Kushner connection. Joshua Kushner, vice chairman of Oscar's board and brother to Jared Kushner, has remained a prominent name in business and politics alike. That visibility might be adding an extra layer of speculation to the mix. But for now, the stock's movement is being driven more by momentum than fundamentals. Oscar is just $3 shy of its all-time highand the retail crowd seems determined to carry it the rest of the way. This article first appeared on GuruFocus.
Yahoo
2 hours ago
- Yahoo
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ('AIM' or the 'Company') (NYSE American: AIM) today announced the receipt of a warning notification (the 'Letter') from the NYSE American LLC (the 'NYSE American') stating that the Company is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the 'Company Guide') requiring stockholders' equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders' deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024. The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025, when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025. On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance. The Company's common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol 'AIM'. The Letter in no way has any effect on such trading and does not affect the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@ in to access your portfolio
